clinical trial manager new york

Stocks2Watch to Host Investor Luncheon with Special Guest, Bruce Campbell from StoneCastle Investment Management, Tuesday November 30th

Stocks2Watch Investor Series today announced their agenda is set for the Investor Luncheon with Special Guest, Bruce Campbell from StoneCastle Investment Management, Tuesday November 30. Individual investors, institutional investors, advisors, and analysts are invited to register now to attend the Luncheon.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

Gain market insight, find investment opportunities, and consider investing in StoneCastle's various funds… all safely in the comfort of your office/home using our latest technology. Confirmed Investor & Finance Professionals will receive a gift certificate to order in lunch on Tuesday, November 30.

LUNCHEON AGENDA: (Eastern Time)

12:00PM: Market Outlook - Bruce Campbell, Portfolio Manager at StoneCastle
12:20PM: Quipt Home Medical (Healthcare) TSX.V: QIPT
12:40PM: PlantFuel Life (Life Science) CSE: FUEL
1:00PM: Levitee Labs (Healthcare) CSE: LVT
1:20PM: New "Stocks2Watch" Picks by Bruce Campbell, Portfolio Manager at StoneCastle

Registration Open to Investors and Finance Professionals >>> This event is suitable for private investors, brokers, fund managers, financial institutions, funds, buy & sell side analysts, influencers, newsletter writers and journalists. The event is not suitable for people pursuing commercial opportunities.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

ABOUT STOCKS2WATCH:

Stocks2Watch hosts online and in-person interactive events for publicly-traded companies to meet and present directly with investors. To learn more about Stocks2Watch and view a complete list of events, please visit www.stocks2watch.ca

NEXT LUNCHEON: Scheduled for Thursday January 20th

CONTACT:

Neil Lock,
info@stocks2watch.ca
604-410-4888

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104215

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Screening closed for all sites and final participants being scheduled for dosing
  • On track for top-line 6-week primary endpoint results in late Q2

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways to Participate in Stifel Virtual CNS Forum

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45 th Annual Health Care Conference at 1:10 pm ET on March 3 rd , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×